A formulation containing biochanin-A with or without its analogues will be beneficial in treating diabetes and diabetic cardiomyopathy, with evidence through increasing IGF1R (insulin-like growth factor 1 receptor), INSR (insulin receptor), and IRS2 (insulin receptor substrate 2) levels, thereby leading to the up-regulation of Lin28 gene and insulin sensitivity (Boominathan L, 2017). Here, IRS2 is linked to diabetic cardiomyopathy.